FIELD: chemistry.
SUBSTANCE: invention relates to N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate. This crystalline N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate is a polymorphic modification of crystalline N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate, which is characterized in that the diffraction pattern of the polymorphic modification contains the 2-theta value of the angle 6.5, 12.9, 16.8, 18.9, 19.3, 19.5, 20.0, 22.4, 22.5, 23.2, 23.8, 25.5, 25.9, 28.8, 30.5, 32.7 and 35.7 degrees. This polymorphic modification has increased stability and improved kinetics of release.
EFFECT: invention also relates to pharmaceutical compositions comprising said crystalline monohydrate, and its use for the preparation of a medicament for the treatment and/or prevention of a viral infection of herpes simplex and/or prevention of transmission of herpes simplex virus.
5 cl, 3 dwg, 8 ex, 5 tbl
